title: Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.
abstract: OBJECTIVE
  The purpose is to investigate the clinical relevance of altered patterns of p27 and Skp2 expression in African-American patients with localized prostate cancer. The abundance of p27, an inhibitor of cell proliferation, is controlled by Skp2-dependent proteolysis.
  
  
  METHODS
  A well-characterized cohort of 162 African-Americans who underwent radical prostatectomy at the Veterans Affairs Medical Center of New York between 1990 and 2000 was studied. We analyzed p27 and Skp2 expression by immunohistochemistry. Altered expression of p27 (defined as <40% tumor cells expressing the protein) and Skp2 (defined as > or ==" BORDER="0">20% tumor cells expressing the protein) were correlated with clinicopathological parameters and time to prostate-specific antigen (PSA) recurrence.
  
  
  RESULTS
  Altered expression of p27 and Skp2 was observed in 112 of 162 (69.1%) and 93 of 162 (57.4%) cases, respectively. Inverse patterns of Skp2 and p27 protein expression were seen in 87 of 162 (53.7%) cases. A marginally significant association was found between Skp2 overexpression and extracapsular extension (P = 0.065). Moreover, patients with Skp2 overexpression had a 2.77 years decreased median time to PSA recurrence compared with patients with low Skp2 expression; however, the difference was not statistically significant. In multivariate analysis, only tumor grade and stage independently predicted PSA recurrence in this cohort.
  
  
  CONCLUSIONS
  Our data suggest a role for Skp2 overexpression in prostate cancer pathogenesis that might not be exclusively related to p27 degradation. More studies are needed to determine the mechanistic role of Skp2 in prostate cancer.
authors.affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
authors.forename: Marija
authors.initials: M
authors.lastname: Drobnjak
authors.forename: Jonathan
authors.initials: J
authors.lastname: Melamed
authors.forename: Samir
authors.initials: S
authors.lastname: Taneja
authors.forename: Kate
authors.initials: K
authors.lastname: Melzer
authors.forename: Rosemary
authors.initials: R
authors.lastname: Wieczorek
authors.forename: Benjamin
authors.initials: B
authors.lastname: Levinson
authors.forename: Anne
authors.initials: A
authors.lastname: Zeleniuch-Jacquotte
authors.forename: David
authors.initials: D
authors.lastname: Polsky
authors.forename: Jay
authors.initials: J
authors.lastname: Ferrara
authors.forename: Roman
authors.initials: R
authors.lastname: Perez-Soler
authors.forename: Carlos
authors.initials: C
authors.lastname: Cordon-Cardo
authors.forename: Michele
authors.initials: M
authors.lastname: Pagano
authors.forename: Iman
authors.initials: I
authors.lastname: Osman
mesh_terms: D001741:Black or African American; D000911:Antibodies, Monoclonal; D044383:Black People; D018797:Cell Cycle Proteins / Q000096:biosynthesis*; D015331:Cohort Studies; D050760:Cyclin-Dependent Kinase Inhibitor p27; D003593:Cytoplasm / Q000378:metabolism; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D015999:Multivariate Analysis; D010641:Phenotype; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000378:metabolism*; D011485:Protein Binding; D012008:Recurrence; D044786:S-Phase Kinase-Associated Proteins / Q000096:biosynthesis*; D013997:Time Factors; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis*
chemical_list: D000911:Antibodies, Monoclonal; D018797:Cell Cycle Proteins; D044786:S-Phase Kinase-Associated Proteins; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D017430:Prostate-Specific Antigen